ETMR
MCID: EMB015
MIFTS: 29

Embryonal Tumor with Multilayered Rosettes (ETMR)

Categories: Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Embryonal Tumor with Multilayered Rosettes

MalaCards integrated aliases for Embryonal Tumor with Multilayered Rosettes:

Name: Embryonal Tumor with Multilayered Rosettes 53
Ependymoblastoma 53 72
Embryonal Tumor with Abundant Neuropil and True Rosettes 53
Neuroectodermal Tumors Primitive 53
Etantr 53
Etmr 53

Classifications:



External Ids:

UMLS 72 C0700367

Summaries for Embryonal Tumor with Multilayered Rosettes

MalaCards based summary : Embryonal Tumor with Multilayered Rosettes, also known as ependymoblastoma, is related to pediatric infratentorial ependymoblastoma and adult ependymoblastoma, and has symptoms including vomiting and headache. An important gene associated with Embryonal Tumor with Multilayered Rosettes is LIN28A (Lin-28 Homolog A). The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone.

Related Diseases for Embryonal Tumor with Multilayered Rosettes

Graphical network of the top 20 diseases related to Embryonal Tumor with Multilayered Rosettes:



Diseases related to Embryonal Tumor with Multilayered Rosettes

Symptoms & Phenotypes for Embryonal Tumor with Multilayered Rosettes

UMLS symptoms related to Embryonal Tumor with Multilayered Rosettes:


vomiting, headache

Drugs & Therapeutics for Embryonal Tumor with Multilayered Rosettes

Drugs for Embryonal Tumor with Multilayered Rosettes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 3 58-05-9 143 6006
3
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
4
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
5
Donepezil Approved Phase 3 120014-06-4 3152
6
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
7
Ondansetron Approved Phase 3 99614-02-5 4595
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
10
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
11
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
15
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
16
Daunorubicin Approved Phase 3 20830-81-3 30323
17
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
18
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
19
Histamine Approved, Investigational Phase 3 51-45-6 774
20
Cyproheptadine Approved Phase 3 129-03-3 2913
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
23 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
24
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
25 Analgesics Phase 3
26 Hormones Phase 3
27 Peripheral Nervous System Agents Phase 3
28 Folic Acid Antagonists Phase 3
29 Vitamin B Complex Phase 3
30 Folate Phase 3
31 Vitamin B9 Phase 3
32 Nucleic Acid Synthesis Inhibitors Phase 3
33 Antidotes Phase 3
34 Protective Agents Phase 3
35 Calcium, Dietary Phase 3
36 Vitamins Phase 3
37 Anti-Bacterial Agents Phase 3
38 Liver Extracts Phase 3
39 Antiemetics Phase 3
40 Autonomic Agents Phase 3
41 Central Nervous System Depressants Phase 3
42 Nootropic Agents Phase 3
43 Cholinesterase Inhibitors Phase 3
44 Cholinergic Agents Phase 3
45 Emetics Phase 3
46 Cola Phase 3
47 Anesthetics, Intravenous Phase 3
48 Narcotics Phase 3
49 Analgesics, Opioid Phase 3
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
2 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
3 Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
5 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Completed NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
6 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
7 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
8 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
10 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
11 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
12 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
13 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
14 Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy Unknown status NCT00180791 Phase 2 Etoposide, carboplatin, melphalan, cisplatin, thiotepa
15 Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours Unknown status NCT00274911 Phase 2 cisplatin;lomustine;vincristine sulfate
16 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
17 A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM Completed NCT01977677 Phase 1, Phase 2 temozolomide;plerixafor
18 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
19 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
20 Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET Completed NCT01542736 Phase 2 Carboplatin;Vincristine
21 A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors Completed NCT00030667 Phase 2 imatinib mesylate
22 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
23 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
24 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
25 A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas Completed NCT00070109 Phase 2 trabectedin
26 Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
27 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
28 A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies Completed NCT02116777 Phase 1, Phase 2 Talazoparib;Temozolomide
29 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
30 A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma Completed NCT00330421 Phase 2 sorafenib tosylate
31 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
32 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
33 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
34 Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years Completed NCT00936156 Phase 2 Chemotherapy (carboplatin, etoposide, thiotepa)
35 A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Completed NCT00563680 Phase 2 AMG 479
36 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
37 A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma Completed NCT00516295 Phase 2 topotecan hydrochloride;vincristine sulfate;cyclophosphamide
38 Phase II Study of Antineoplastons A10 and AS2-1 In Children With Primitive Neuroectodermal Tumors Completed NCT00003460 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
39 A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors Completed NCT00047177 Phase 2 Oxaliplatin
40 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
41 A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT) Completed NCT00055952 Phase 2 exatecan mesylate
42 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
43 A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias Completed NCT01154816 Phase 2 Alisertib
44 A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
45 Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
46 Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
47 INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
48 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
49 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
50 Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2

Search NIH Clinical Center for Embryonal Tumor with Multilayered Rosettes

Genetic Tests for Embryonal Tumor with Multilayered Rosettes

Anatomical Context for Embryonal Tumor with Multilayered Rosettes

MalaCards organs/tissues related to Embryonal Tumor with Multilayered Rosettes:

41
Brain, T Cells, Bone, Lung, Spinal Cord, Liver, Pineal

Publications for Embryonal Tumor with Multilayered Rosettes

Articles related to Embryonal Tumor with Multilayered Rosettes:

(show top 50) (show all 281)
# Title Authors PMID Year
1
Medulloepithelioma with heterologous osteoid component: a case report and review of literature. 38
30617578 2019
2
Molecular Pathology of Tumors of the Central Nervous System. 38
31124566 2019
3
Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. 38
30879172 2019
4
Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. 38
30967140 2019
5
Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. 38
30720470 2019
6
Radiation for ETMR: Literature review and case series of patients treated with proton therapy. 38
30582019 2019
7
Embryonal Tumor with Multilayered Rosettes in a 3-Year-Old Girl: Case Report. 38
28191622 2019
8
Integration of a Personalized Molecular Targeted Therapy into the Multimodal Treatment of Refractory Childhood Embryonal Tumor with Multilayered Rosettes (ETMR). 38
31011318 2019
9
A Congenital Case of Ependymoblastoma: A Rare and Aggressive Brain Tumor. 38
29432310 2019
10
Embryonal tumor with multilayered rosettes: illustrative case and review of the literature. 38
30215121 2018
11
Central Nervous System-type Neuroepithelial Tumors and Tumor-like Proliferations Developing in the Gynecologic Tract and Pelvis: Clinicopathologic Analysis of 23 Cases. 38
30074494 2018
12
Sellar Embryonal Tumor: A Case Report and Review of the Literature. 38
30459893 2018
13
Embryonal Tumor with Multilayered Rosettes, C19MC-Altered: Clinical, Pathological, and Neuroimaging Findings. 38
29797626 2018
14
Embryonal Tumor with Multilayered Rosettes Presenting with Intermittent Third Nerve Palsy. 38
29880079 2018
15
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. 38
29521646 2018
16
Extracranial extra-CNS spread of embryonal tumor with multilayered rosettes (ETMR): case series and systematic review. 38
29177676 2018
17
Embryonal tumor with multilayered rosettes: Diagnosis on intra-operative squash smear. 38
29514411 2018
18
Four Levels of Diagnosis in the Rare Pediatric Embryonal Tumor of the CNS Called Embryonal Tumor with Multilayered Rosettes. 38
29528833 2018
19
Embryonal Tumors of the Central Nervous System: From the Radiologic Pathology Archives. 38
29528832 2018
20
Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. 38
29248974 2018
21
LIN28A, a sensitive immunohistochemical marker for Embryonal Tumor with Multilayered Rosettes (ETMR), is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT). 38
28744687 2017
22
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. 38
28482026 2017
23
Rare Brain Tumor in a Neonate. 38
30065500 2017
24
A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016. 38
29204027 2017
25
Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). 38
28508928 2017
26
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. 38
28592714 2017
27
Lymph node metastasis of presacral ependymoblastoma in a young child. 38
28215462 2017
28
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. 38
28453743 2017
29
Overexpression of Lin28b in Neural Stem Cells is Insufficient for Brain Tumor Formation, but Induces Pathological Lobulation of the Developing Cerebellum. 38
27039094 2017
30
Embryonal tumor with multilayered rosettes, C19MC-altered: Report of an extremely rare malignant pediatric central nervous system neoplasm. 38
29230288 2017
31
Atypical teratoid/rhabdoid tumors with multilayered rosettes in the pineal region. 38
27307151 2016
32
Embryonal Tumor With Abundant Neuropil and True Rosettes: A Distinct Immunohistochemical Pattern. 38
26658063 2016
33
Embryonal tumors with multilayered rosettes in children: the SFCE experience. 38
26438544 2016
34
Pediatric brain tumors in a low/middle income country: does it differ from that in developed world? 38
26514358 2016
35
Review of the Dielectric Properties of Animal and Human Tumors Determined from In Vivo Measurements. 38
29199579 2016
36
Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. 38
26183384 2015
37
Sacrococcygeal ependymoblastoma. 38
26493054 2015
38
[Clinicopathologic features of embryonal tumor with multilayered rosettes and gene analysis on chromosome 19q13.42]. 38
26888507 2015
39
Embryonal tumor with multilayered rosettes of the fourth ventricle: case report. 38
26252622 2015
40
Uncommon pediatric tumors of the posterior fossa: pathologic and molecular features. 38
26351226 2015
41
Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. 38
25916887 2015
42
Posterior fossa ependymoblastoma diagnosed in the second month of life: uneventful 12 years survival after gross total resection followed by chemotherapy. 38
26251773 2015
43
[Embryonal Tumors with Multilayer Rosettes--Rare Central Nervous System Tumors in Infants]. 38
26299744 2015
44
Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. 38
25077668 2014
45
Embryonal brain tumors. 38
25415685 2014
46
MET T992I mutation in a case of ependymoblastoma/embryonal tumour with multilayered rosettes. 38
25194039 2014
47
MRI characteristics of ependymoblastoma: results from 22 centrally reviewed cases. 38
24948504 2014
48
Congenital cerebellar embryonal tumor with multilayered rosettes: report of a rare case. 38
25308038 2014
49
Embryonal tumor with abundant neuropil and true rosettes with only one structure suggestive of an ependymoblastic rosette. 38
25186165 2014
50
Embryonal tumor with multilayered rosettes (ETMR): signed, sealed, delivered …. 38
25012402 2014

Variations for Embryonal Tumor with Multilayered Rosettes

Expression for Embryonal Tumor with Multilayered Rosettes

Search GEO for disease gene expression data for Embryonal Tumor with Multilayered Rosettes.

Pathways for Embryonal Tumor with Multilayered Rosettes

GO Terms for Embryonal Tumor with Multilayered Rosettes

Sources for Embryonal Tumor with Multilayered Rosettes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....